Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: J Neurooncol. 2018 Apr 20;139(2):399–409. doi: 10.1007/s11060-018-2877-6

Fig. 3. Anatomic MRI and 18F-FDOPA PET measurements across IDH mutation status and MGMT promoter methylation status.

Fig. 3

A) Volume of contrast enhancement, B) volume of T2 hyperintensity, and C) 18F-FDOPA PET T/N SUVmax ratio comparisons between isocitrate dehydrogenase (IDH) mutant (IDHMUT) and wild type (IDHWT) gliomas (n=39 evaluable). D) Volume of contrast enhancement, E) volume of T2 hyperintensity, and F) 18F-FDOPA PET T/N SUVmax ratio comparisons between O6-methylguanine-DNA methyltransferase (MGMT) promoter methylated and unmethylated gliomas (n=33 evaluable).